Ane Beatriz Mautari Niwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ane Beatriz Mautari Niwa has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Richard Fitzpatrick
2 shared publicationsAna Paula F. Mello
Clínica Nuno Osório, São Paulo‐SP, Brazil
1 shared publicationIsabella Guiha
1 shared publicationLuís Antonio Torezan
Dermatology Division, Hospital das Clínicas, Medical School, University of São Paulo, São Paulo‐SP, Brazil
1 shared publicationMarcello Menta Simonsen Nico
Universidade de São Paulo, Brasil
1 shared publicationMitchel P. Goldman
Goldman, Butterwick, Fitzpatrick, Groff & Fabi Cosmetic Laser Dermatology, San Diego, California
1 shared publication
Latest Publications
- 25 February 2013
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 45 (2) , 123-129
Endoluminal laser delivery mode and wavelength effects on varicose veins in anEx vivomodel
Background and Objectives Endovenous laser ablation (EVLA) has been shown to be effective for the elimination of saphenous veins and associated reflux. Mechanism is known to be heat related, but precise way in which heat causes vein ablation is not completely known. This study aimed to determine the effects of various endovenous laser wavelengths and delivery modes on ex vivo human vein both macroscopically and microscopically. We also evaluated whether protected‐tip fibers, consisting of prototype silica fibers with a metal tube over the distal end, reduced vein wall perforations compared with non‐protected‐tip fibers. Materials and Methods An ex vivo EVLA model with human veins harvested during ambulatory phlebectomy procedures was used. Six laser fiber combinations were tested: 810 nm continuous wave (CW) diode laser with a flat tip fiber, 810 CW diode laser with a protected tip fiber, 1,320 nm pulsed Nd:YAG laser, 1,310 nm CW diode laser, 1,470 nm CW diode laser, and 2,100 nm pulsed Ho:YAG laser. Results Perforation or full thickness necrosis of a portion of the vein wall was observed in 5/11 (45%), 0/11 (0%), 3/22 (14%), 7/11 (64%), 4/6 (67%), and 5/10 (50%) of cross‐sections of veins treated with the 810 nm CW diode laser with a flat tip fiber, the 810 CW diode laser with a protected tip fiber, the 1,320 nm pulsed Nd:YAG laser, the 1,310 nm CW diode laser, the 1,470 nm CW diode laser, and the 2,100 nm pulsed Ho:YAG laser, respectively. Conclusion Our results have shown that the delivery mode, pulsed Nd:YAG versus CW, may be just as important as the wavelength. Therefore, the 1,310 nm CW laser may not be equivalent to the 1,320 nm pulsed laser. In addition, protected 810 nm fibers may be less likely to yield wall perforations than their non‐protected counterparts. Lasers Surg. Med. 45: 123–129, 2013.
- 25 February 2013
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 45 (2) , 123-129
Endoluminal laser delivery mode and wavelength effects on varicose veins in anEx vivomodel
Background and Objectives Endovenous laser ablation (EVLA) has been shown to be effective for the elimination of saphenous veins and associated reflux. Mechanism is known to be heat related, but precise way in which heat causes vein ablation is not completely known. This study aimed to determine the effects of various endovenous laser wavelengths and delivery modes on ex vivo human vein both macroscopically and microscopically. We also evaluated whether protected‐tip fibers, consisting of prototype silica fibers with a metal tube over the distal end, reduced vein wall perforations compared with non‐protected‐tip fibers. Materials and Methods An ex vivo EVLA model with human veins harvested during ambulatory phlebectomy procedures was used. Six laser fiber combinations were tested: 810 nm continuous wave (CW) diode laser with a flat tip fiber, 810 CW diode laser with a protected tip fiber, 1,320 nm pulsed Nd:YAG laser, 1,310 nm CW diode laser, 1,470 nm CW diode laser, and 2,100 nm pulsed Ho:YAG laser. Results Perforation or full thickness necrosis of a portion of the vein wall was observed in 5/11 (45%), 0/11 (0%), 3/22 (14%), 7/11 (64%), 4/6 (67%), and 5/10 (50%) of cross‐sections of veins treated with the 810 nm CW diode laser with a flat tip fiber, the 810 CW diode laser with a protected tip fiber, the 1,320 nm pulsed Nd:YAG laser, the 1,310 nm CW diode laser, the 1,470 nm CW diode laser, and the 2,100 nm pulsed Ho:YAG laser, respectively. Conclusion Our results have shown that the delivery mode, pulsed Nd:YAG versus CW, may be just as important as the wavelength. Therefore, the 1,310 nm CW laser may not be equivalent to the 1,320 nm pulsed laser. In addition, protected 810 nm fibers may be less likely to yield wall perforations than their non‐protected counterparts. Lasers Surg. Med. 45: 123–129, 2013.
- 19 December 2012
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 45 (2) , 95-101
Treatment of melasma with the 1,927‐nm fractional thulium fiber laser: A retrospective analysis of 20 cases with long‐term follow‐up
Background: Melasma is a common acquired symmetrical hyperpigmentation that is often recurrent and refractory.Objectives: To investigate the efficacy and safety of a single administration of high‐density fractional thulium fiber laser (1,927 nm) for the treatment of refractory melasma in 20 patients.Materials and Methods: A retrospective chart and photographs review of 20 women (Fitzpatrick skin type II–IV) with clinical diagnosis of melasma treated with the 1,927‐nm fractionated thulium laser at 10 or 20 mJ/cm2, with 60–70% surface area coverage. Four investigators independently evaluated Melasma Area Severity Index (MASI) scores before, 4 weeks, 3–6 months, and 6–12 months after treatment.Results: Mean MASI scores decreased dramatically from 13.2 ± 5.4 before treatment to 8.5 ± 3.5 at 4 weeks after laser treatment (P = 0.004). Patient assessment revealed that 12 of the 20 subjects had more than 50% clearance of their melasma. Recurrence was reported by 7 out of 15 patients who were successfully followed‐up (mean 10.2 months). Two patients developed postinflammatory hyperpigmentation that subsided with topical bleaching after 3 months.Conclusion: High‐density coverage fractional 1,927‐nm thulium laser proved to be safe and effective for melasma with long‐term remission. Lasers Surg. Med. 45: 95–101, 2013.
- 19 December 2012
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 45 (2) , 95-101
Treatment of melasma with the 1,927‐nm fractional thulium fiber laser: A retrospective analysis of 20 cases with long‐term follow‐up
Background: Melasma is a common acquired symmetrical hyperpigmentation that is often recurrent and refractory.Objectives: To investigate the efficacy and safety of a single administration of high‐density fractional thulium fiber laser (1,927 nm) for the treatment of refractory melasma in 20 patients.Materials and Methods: A retrospective chart and photographs review of 20 women (Fitzpatrick skin type II–IV) with clinical diagnosis of melasma treated with the 1,927‐nm fractionated thulium laser at 10 or 20 mJ/cm2, with 60–70% surface area coverage. Four investigators independently evaluated Melasma Area Severity Index (MASI) scores before, 4 weeks, 3–6 months, and 6–12 months after treatment.Results: Mean MASI scores decreased dramatically from 13.2 ± 5.4 before treatment to 8.5 ± 3.5 at 4 weeks after laser treatment (P = 0.004). Patient assessment revealed that 12 of the 20 subjects had more than 50% clearance of their melasma. Recurrence was reported by 7 out of 15 patients who were successfully followed‐up (mean 10.2 months). Two patients developed postinflammatory hyperpigmentation that subsided with topical bleaching after 3 months.Conclusion: High‐density coverage fractional 1,927‐nm thulium laser proved to be safe and effective for melasma with long‐term remission. Lasers Surg. Med. 45: 95–101, 2013.
- 1 July 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (7) , 995-1001
Repigmentation of Hypopigmented Scars Using an Erbium-Doped 1,550-nm Fractionated Laser and Topical Bimatoprost
Hypopigmented scarring is a challenging condition to treat, with current treatments showing limited efficacy and temporary results. Nonablative fractional resurfacing has been demonstrated to be an effective and safe modality in the treatment of hypopigmented scars. To demonstrate the efficacy and safety of combining fractional resurfacing with topical bimatoprost and topical tretinoin or pimecrolimus for the treatment of hypopigmented scars. Fourteen patients with hypopigmented scars were treated with a mean of 4.5 sessions of a fractionated 1,550-nm erbium-doped laser at 4- to 8-week intervals and subsequently started topical bimatoprost and tretinoin or pimecrolimus. An independent physician evaluated digital photographs taken before and 4 weeks after the last laser treatment using a quartile grading scale (grade 1, ≤25% improvement; grade 2, 26-50% improvement; grade 3, 51-75% improvement; grade 4, >75% improvement). Five patients had >75% improvement in hypopigmentation, and 12 had >50% improvement. After a mean follow-up of 20.1 months, all patients demonstrated prolonged results. Side effects were limited to transitory post-treatment edema and erythema. The combination of fractional resurfacing, topical bimatoprost, and tretinoin or pimecrolimus is a potential effective resource for the treatment of hypopigmented scars, with long-lasting results.
- 1 July 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (7) , 995-1001
Repigmentation of Hypopigmented Scars Using an Erbium-Doped 1,550-nm Fractionated Laser and Topical Bimatoprost
Hypopigmented scarring is a challenging condition to treat, with current treatments showing limited efficacy and temporary results. Nonablative fractional resurfacing has been demonstrated to be an effective and safe modality in the treatment of hypopigmented scars. To demonstrate the efficacy and safety of combining fractional resurfacing with topical bimatoprost and topical tretinoin or pimecrolimus for the treatment of hypopigmented scars. Fourteen patients with hypopigmented scars were treated with a mean of 4.5 sessions of a fractionated 1,550-nm erbium-doped laser at 4- to 8-week intervals and subsequently started topical bimatoprost and tretinoin or pimecrolimus. An independent physician evaluated digital photographs taken before and 4 weeks after the last laser treatment using a quartile grading scale (grade 1, ≤25% improvement; grade 2, 26-50% improvement; grade 3, 51-75% improvement; grade 4, >75% improvement). Five patients had >75% improvement in hypopigmentation, and 12 had >50% improvement. After a mean follow-up of 20.1 months, all patients demonstrated prolonged results. Side effects were limited to transitory post-treatment edema and erythema. The combination of fractional resurfacing, topical bimatoprost, and tretinoin or pimecrolimus is a potential effective resource for the treatment of hypopigmented scars, with long-lasting results.
- 1 May 2009
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 35 (5) , 773-778
Fractional Photothermolysis for the Treatment of Hypertrophic Scars
Hypertrophic scars are common problems and represent a challenging condition to treat. Fractional photothermolysis has been effective at resurfacing photodamaged skin, acne scars, and atrophic scars, but there are few reports on its use for hypertrophic scars. To evaluate the safety and efficacy of 1,550-nm erbium-doped fiber laser treatment of hypertrophic scars in eight patients. Eight patients (skin phototypes II-IV) with hypertrophic scars received monthly treatments with a 1,550-nm erbium-doped fiber laser. Energy settings ranged from 35 to 50 mJ, and eight to 10 passes were applied with treatment levels 6 to 8. An independent physician evaluator assessed the treatment response by comparing pre- and posttreatment clinical photographs using a quartile grading scale (grade 1, < or =25%=minimal to no improvement; grade 2, 26-50%=moderate improvement; grade 3, 51-75%=marked improvement; grade 4, >75%=near total improvement. At four weeks after the last treatment session, a mean grade of 2.4 was achieved based on an independent physician's clinical assessment. Improvement in pigmentation occurred in all hyperpigmented scars. Hypertrophic scars can be effectively and safely improved with 1,550-nm erbium-doped fiber laser treatment.
- 1 May 2009
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 35 (5) , 773-778
Fractional Photothermolysis for the Treatment of Hypertrophic Scars
Hypertrophic scars are common problems and represent a challenging condition to treat. Fractional photothermolysis has been effective at resurfacing photodamaged skin, acne scars, and atrophic scars, but there are few reports on its use for hypertrophic scars. To evaluate the safety and efficacy of 1,550-nm erbium-doped fiber laser treatment of hypertrophic scars in eight patients. Eight patients (skin phototypes II-IV) with hypertrophic scars received monthly treatments with a 1,550-nm erbium-doped fiber laser. Energy settings ranged from 35 to 50 mJ, and eight to 10 passes were applied with treatment levels 6 to 8. An independent physician evaluator assessed the treatment response by comparing pre- and posttreatment clinical photographs using a quartile grading scale (grade 1, < or =25%=minimal to no improvement; grade 2, 26-50%=moderate improvement; grade 3, 51-75%=marked improvement; grade 4, >75%=near total improvement. At four weeks after the last treatment session, a mean grade of 2.4 was achieved based on an independent physician's clinical assessment. Improvement in pigmentation occurred in all hyperpigmented scars. Hypertrophic scars can be effectively and safely improved with 1,550-nm erbium-doped fiber laser treatment.
- Open Access
- 1 December 2008
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 83 (6) , 549-553
Síndrome carcinóide: relato de caso
Os tumores carcinóides são raros, com incidência aproximada de um a dois casos por 100.000 habitantes. Estima-se que a síndrome carcinóide - que se caracteriza por flushing, diarréia, dor abdominal e, em menor freqüência, pelagra, broncoespasmo e doença valvar cardíaca - ocorra em menos de 10% dos doentes. Entretanto, nos casos avançados a incidência varia de 40 a 50%. Estudos retrospectivos e de série de casos mostram que as manifestações cutâneas são freqüentes nessa entidade, embora sejam raramente relatadas. Apresenta-se um caso de síndrome carcinóide diagnosticadoa partir das manifestações dermatológicas.
- 1 December 2008
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 83 (6) , 549-553
Open AccessSíndrome carcinóide: relato de caso
Os tumores carcinóides são raros, com incidência aproximada de um a dois casos por 100.000 habitantes. Estima-se que a síndrome carcinóide - que se caracteriza por flushing, diarréia, dor abdominal e, em menor freqüência, pelagra, broncoespasmo e doença valvar cardíaca - ocorra em menos de 10% dos doentes. Entretanto, nos casos avançados a incidência varia de 40 a 50%. Estudos retrospectivos e de série de casos mostram que as manifestações cutâneas são freqüentes nessa entidade, embora sejam raramente relatadas. Apresenta-se um caso de síndrome carcinóide diagnosticadoa partir das manifestações dermatológicas.